Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Anileridine is an opioid analgesic used to treat moderate to severe pain. Narcotic analgesics act in the central nervous system (CNS) to relieve pain.
- Mechanism
- Curator reviewed
Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Opioids such as anileridine close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
- Primary indication
- For treatment and management of pain (systemic) and for use as an anesthesia adjunct.Curator reviewed
- Formula / weight
- C22H28N2O2 · 352.4699 g/mol (avg)
- First approval
- Canada, 1966
- Code names
- IDS-NA-012
Resolves to
LKYQLAWMNBFNJT-UHFFFAOYSA-NSMILESCCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1What you can answer from here — as of September 13, 2026
Which drugs share a target with Anileridine, and which of those have an active Phase 3 trial?